RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RAPT Therapeutics Stock

RAPT Therapeutics ROA 2024

RAPT Therapeutics ROA

-0.67

Ticker

RAPT

ISIN

US75382E1091

WKN

A2PNYQ

In 2024, RAPT Therapeutics's return on assets (ROA) was -0.67, a 113.95% increase from the -0.31 ROA in the previous year.

RAPT Therapeutics Aktienanalyse

What does RAPT Therapeutics do?

Rapt Therapeutics Inc. is an emerging pharmaceutical company that was originally founded in 2015 under the name "FLX Bio". The company is based in San Francisco, California. Rapt is the name of the biological process that the company uses to identify and develop drug candidates. Rapt Therapeutics specializes in developing innovative immunotherapies for cancer treatment. The goal is to harness the power of the immune system to support the body in fighting cancer. The company focuses on developing prophylactic cancer vaccines and immunotherapies that aim to directly combat cancer cells and strengthen the body's defenses. The company's business model is based on an innovative technology platform that is able to identify antibodies and other molecules that activate the RAPT process, which is important for combating cancer cells. With this technology, Rapt Therapeutics can quickly and accurately identify potential drug candidates that are suitable for the development of cancer immunotherapies. At the time of its founding, Rapt primarily focused on developing immunotherapeutics for solid tumors, a type of cancer that originates in a specific tissue in the body and does not spread to adjacent tissues or organs. However, the company has since expanded its portfolio to include the development of therapeutics for hematological cancers such as leukemia and lymphoma. Rapt Therapeutics employs a pipeline-based research strategy. The pipeline-based research strategy means that Rapt Therapeutics develops a variety of drug candidates targeting different disease indications. The drug candidates are then tested in different phases of clinical development to evaluate their efficacy and safety. To date, Rapt Therapeutics has four drug candidates in clinical development. The first candidate, RPT193, is currently being tested in phase 1 clinical trials for the treatment of various solid tumors. The second candidate, RPT835, is currently in preclinical development and targets the treatment of leukemia. The third candidate, FLX475, is also in preclinical development and targets the treatment of multiple sclerosis. The fourth candidate, FLX475, is currently in phase 1 clinical trials and targets the treatment of certain solid tumors. In addition, Rapt Therapeutics has also entered into a number of partnerships with other pharmaceutical companies. In 2018, Rapt Therapeutics signed a strategic collaboration with AstraZeneca to accelerate the development of RPT193. Under this collaboration, AstraZeneca will test RPT193 in clinical trials. In 2019, Rapt Therapeutics entered into a research and development collaboration with Hanmi Pharmaceutical Co. Ltd. to accelerate the discovery, development, and commercialization of drug candidates for cancer and other diseases. Rapt Therapeutics is pursuing a long-term strategy to become a leading company in immunotherapy development. By continuing its research and development of cancer immunotherapies, Rapt has the potential to improve the lives of millions of people suffering from cancer and other serious diseases. RAPT Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding RAPT Therapeutics's Return on Assets (ROA)

RAPT Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing RAPT Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider RAPT Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in RAPT Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about RAPT Therapeutics stock

What is the Return on Assets (ROA) of RAPT Therapeutics this year?

The Return on Assets (ROA) of RAPT Therapeutics is -0.67 undefined this year.

What was the ROA of RAPT Therapeutics compared to the previous year?

The ROA of RAPT Therapeutics has increased by 113.95% compared to the previous year.

What consequences do high ROA have for investors of RAPT Therapeutics?

A high ROA is advantageous for investors of RAPT Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in RAPT Therapeutics?

A low ROA can be unfavorable for investors of RAPT Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of RAPT Therapeutics affect the company?

An increase in ROA of RAPT Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of RAPT Therapeutics impact the company?

A reduction in the ROA of RAPT Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of RAPT Therapeutics?

Some factors that can influence the ROA of RAPT Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of RAPT Therapeutics important for investors?

The ROA of RAPT Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can RAPT Therapeutics take to improve ROA?

To improve ROA, RAPT Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does RAPT Therapeutics pay?

Over the past 12 months, RAPT Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RAPT Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of RAPT Therapeutics?

The current dividend yield of RAPT Therapeutics is .

When does RAPT Therapeutics pay dividends?

RAPT Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RAPT Therapeutics?

RAPT Therapeutics paid dividends every year for the past 0 years.

What is the dividend of RAPT Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RAPT Therapeutics located?

RAPT Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von RAPT Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RAPT Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did RAPT Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of RAPT Therapeutics in the year 2023?

In the year 2023, RAPT Therapeutics distributed 0 USD as dividends.

In which currency does RAPT Therapeutics pay out the dividend?

The dividends of RAPT Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The RAPT Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von RAPT Therapeutics

Our stock analysis for RAPT Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RAPT Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.